KRTX * Stock Overview
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Karuna Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3,226.17 |
| 52 Week High | US$3,963.40 |
| 52 Week Low | US$3,093.15 |
| Beta | 1.19 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 26.72% |
| 5 Year Change | n/a |
| Change since IPO | 26.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| KRTX * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how KRTX * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how KRTX * performed against the MX Market.
Price Volatility
| KRTX * volatility | |
|---|---|
| KRTX * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: KRTX * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine KRTX *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 210 | Bill Meury | www.karunatx.com |
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder.
Karuna Therapeutics, Inc. Fundamentals Summary
| KRTX * fundamental statistics | |
|---|---|
| Market cap | Mex$209.13b |
| Earnings (TTM) | -Mex$7.42b |
| Revenue (TTM) | Mex$11.20m |
Over9,999x
P/S Ratio-28.2x
P/E RatioIs KRTX * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRTX * income statement (TTM) | |
|---|---|
| Revenue | US$654.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$654.00k |
| Other Expenses | US$434.33m |
| Earnings | -US$433.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.37 |
| Gross Margin | 100.00% |
| Net Profit Margin | -66,311.93% |
| Debt/Equity Ratio | 0% |
How did KRTX * perform over the long term?
See historical performance and comparison